Richard P. Baum

机构：Helios Dr. Horst Schmidt Kliniken Wiesbaden, Hessische Hochschule für Polizei und Verwaltung · ORCID：0000-0003-1723-0075

发表论文 620 篇 · 总被引 25524 次 · h-index 73

代表论文

• Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany (2025 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 9)
• Current status of FAP therapy in solid tumors (2025 · Seminars in Nuclear Medicine · 被引 8)
• Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma (2025 · Clinical Nuclear Medicine · 被引 7)
• Optimizing theranostics chatbots with context-augmented large language models (2025 · Theranostics · 被引 7)
• Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer (2025 · Cancers · 被引 7)
• Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival (2025 · Cancers · 被引 6)